Mesoblast’s Stem-Cell Treatment Shows Improvement In Rheumatoid Arthritis Patients
Australia-based regenerative medicine company Mesoblast Ltd. announced Monday that experiments it was carrying out as a part of stem-cell treatment have led to significant improvements of symptoms and disease activity in rheumatoid arthritis patients who were unable to get relief through widely used biotech medicines.
Rheumatoid arthritis is a chronic autoimmune disease that is found in about one percent of the world’s population. The disease affects the synovial membrane of multiple joints, eventually leading to cartilage and bone destruction.